Ana Niebla-Marin

Bellaterra, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology
Published: November 03, 2025

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Journal: Blood advances
Published: November 19, 2024

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.

Journal: Haematologica
Published: February 05, 2024

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.

Journal: Blood advances
Published: January 29, 2024

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.

Journal: Blood
Published: December 06, 2023

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.

Journal: EJHaem
Published: June 07, 2023

[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage.

[Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage.

Journal: Actas dermo-sifiliograficas
Published: May 10, 2023

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.

Journal: Blood advances
Published: March 07, 2022

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.

Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.

Journal: Leukemia & lymphoma
Published: February 07, 2022

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.

IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.

Journal: International journal of hematology
Published: February 02, 2022

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.

Journal: Leukemia & lymphoma
Published: January 20, 2022

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.

Journal: Blood
Published: January 18, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026